Alumis Inc. Common Stock (ALMS)
$8.39 -$0.18 (-2.01%) 4:38 PM 12/13/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$630.53M -
Day's Range
$8.29 - $8.65 -
Volume
140,329 -
52 Week Low / High
$7.66 - $16.00 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- 4
- Strong Buy
- 2
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $32.33
- Target Price
Company News
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...
-
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' — Oct 10th, 2024
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation (NYSE:TGT) ri...
Similar Stocks
Portfolio
Comprised of 1 portfolios